CC
MRKR icon

Caxton Corporation’s Marker Therapeutics MRKR Stock Holding History

Caxton Corporation’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-2,392
Closed -$189K – 42
2019
Q2 		$189K Sell
2,392
-1,845
-44% -$110K 0.21% 30
2019
Q1 		$280K Sell
4,237
-1,096
-21% -$64K 0.26% 18
2018
Q4 		$296K Sell
5,333
-2,821
-35% -$206K 0.36% 19
2018
Q3 		$738K Sell
8,154
-313
-4% -$26.9K 0.68% 13
2018
Q2 		$798K Buy
+8,467
New +$432K 0.28% 13

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Caxton Corporation's MRKR Position: Q3 2019 in Review

Caxton Corporation sold out of Marker Therapeutics (MRKR) in Q3 2019, closing a stake of 2,392 shares — an estimated $189K sold.

Caxton Corporation first reported a position in MRKR in Q2 2018 and held it in 5 quarters. The position peaked at $798K in Q2 2018. 73 funds tracked by Wall St. Rank hold MRKR as of Q3 2019.

  • Caxton Corporation reported no remaining Marker Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Caxton Corporation sold 2,392 Marker Therapeutics shares in Q3 2019, an estimated $189K.
  • Caxton Corporation first reported a position in Marker Therapeutics in Q2 2018 and held it in 5 quarters.
  • Caxton Corporation's Marker Therapeutics position peaked at $798K in Q2 2018.
  • 73 funds tracked by Wall St. Rank held Marker Therapeutics as of Q3 2019.

Based on Caxton Corporation's 13F filing for Q3 2019, filed 14 Nov 2019.